Risk factors related to hypertension among patients in a cohort living with HIV/AIDS

Brazilian Journal of Infectious Diseases

Volumn 14, Issue 3, 2010, Pages 281-287

  de Arruda Jr , Evanizio Roque ^a   Lacerda, Heloisa Ramos ^b   Moura, Libia Cristina Rocha Vilela ^b   de Albuquerque, Maria de Fatima Pessoa Militão ^c   de Barros Miranda Filho, Democrito ^b   Diniz, George Tadeu Nunes ^c   de Albuquerque, Valeria Maria Gonçalves ^b   Amaral, Josefina Cláudia Zirpoli ^b   de Arraes Ximenes, Ricardo Alencar ^b   Monteiro, Verônica Soares ^b  

^a FEDERAL UNIVERSITY OF PARAÍBA   (Brazil)

^b FEDERAL UNIVERSITY OF PERNAMBUCO   (Brazil)

^c INSTITUTO OSWALDO CRUZ   (Brazil)

Author keywords

Antiretroviral therapy; Cardiovascular risk; HIV AIDS; Hypertension

Indexed keywords

ANTIRETROVIRUS AGENT; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROTEINASE INHIBITOR; TRIACYLGLYCEROL;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGE DISTRIBUTION; ARTICLE; BLOOD PRESSURE MEASUREMENT; BODY MASS; BRAZIL; CASE CONTROL STUDY; CD4 LYMPHOCYTE COUNT; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CONTROLLED STUDY; DIETARY INTAKE; DISEASE ASSOCIATION; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; LIPODYSTROPHY; MAJOR CLINICAL STUDY; MALE; PREVALENCE; SEX DIFFERENCE; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; VIRUS LOAD; WEIGHT CONTROL; WEIGHT GAIN;

EID: 77957942000     PISSN: 14138670     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1413-8670(10)70057-x     Document Type: Article

References (27)

1. Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 2008; 372:293-9.
2. Hadigan C, Meigs JB, Corcoran C et al. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis 2001; 32:130-9.
3. Baekken M, Os I, Sandvik L et al. Hypertension in an urban HIV-positive population compared with the general population: influence of combination antiretroviral therapy. J Hypertens 2008; 26:2126-33.
4. DAD Study Group, Friis-Møller N, Reiss P, Sabin CA et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007; 356:1723-35.
5. Mary-Krause M, Cotte L, Simon A et al. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS 2003; 17:2479-86.
6. Yusuf S, Hawken S, Ounpuu S et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): a case control study. Lancet 2004; 364:937-52.
7. Winston J, Klotman PE. HIV-associated nephropathy. Mt Sinai J Med 1998; 65:27-32.
8. Aoun S, Ramos E. Hypertension in the HIV-infected patient. Curr Hypertens Rep 2000; 2:478-81.
9. Sattler FR, Qian D, Louie S et al. Elevated blood pressure in subjects with lipodystrophy. AIDS 2001; 15:2001-10.
10. Chow DC, Souza SA, Chen R et al. Elevated blood pressure in HIV-infected individuals receiving highly active antiretroviral therapy. HIV Clin Trials 2003; 4:411-6.
11. Gazzaruso C, Bruno R, Garzaniti A et al. Hypertension among HIV patients: prevalence and relationships to insulin resistance and metabolic syndrome. J Hypertension 2003; 21:1377-82.
12. Galindo Puerto MJ. AHT and HIV - a new problem? Nutr Metab Disord HIV Infect 2002; 1:33-7.
13. Bergersen BM, Sandvik L, Dunlop O et al. Prevalence of hypertension in HIV-positive patients on highly active retroviral therapy (HAART) compared with HAART-naive and HIVnegative controls: results from a Norwegian study of 721 patients. Eur J Clin Microbiol Infect Dis 2003; 22:731-6.
14. Palacios R, Santos J, García A et al. Impact of highly active antiretroviral therapy on blood pressure in HIV-infected patients. A prospective study in a cohort of naive patients. HIV Med 2006; 7:10-5.
15. Coloma Conde AG, Alvarez Albarrán M, Roca-Cusachs Coll A et al. Prevalence of arterial hypertension and lipid profi le in HIV patients. Med Clin (Barc) 2008;131:681-4.
16. Dubé MP, Lipshultz SE, Fichenbaum CJ et al. Effects of HIV infection and antiretroviral therapy on the heart and vasculature. Circulation 2008; 118:e36-e40.
17. Thiébaut R, El-Sadr WM, Friis-Møller N et al. and Data Collection of Adverse events of anti-HIV Drugs Study Group. Predictors of hypertension and changes of blood pressure in HIV-infected patients. Antivir Ther 2005; 10:811-23.
18. Crane HM, Van Rompaey SE, Kitahata MM. Antiretroviral medications associated with elevated blood pressure among patients receiving highly active antiretroviral therapy. AIDS 2006; 20:1019-26.
19. Chobanian AV, Bakris GL, Black HR et al. and Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 2003; 42:1206-52.
20. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285:2486-96.
21. Khalsa A, Karim R, Mack WJ et al. Correlates of prevalent hypertension in a large cohort of HIV-infected women: Womens Interagency HIV Study. AIDS 2007; 21:2539-41.
22. Atlas Corações do Brasil, v 1. Sociedade Brasileira de Cardiologia, Abril 1, 2009. Available at: http://prevencao.cardiol.br/campanhas/coracoesdobrasil/atlas/default.asp/
23. Passos VMA, Assis TD, Barreto SM. Hypertension in Brazil: Estimates from population-based prevalence studies. Epidemiologia e Serviços de Saúde 2006; 15:35-45.
24. Kotler DP. HIV and antiretroviral therapy: lipid abnormalities and associated cardiovascular risk in HIV-infected patients. J Acquir Immune Defic Syndr 2008; 49(Suppl2):79-85.
25. Brazilian Ministry of Health, National Program of STD/ AIDS 2008. Consensus for the treatment of adults and adolescents with HIV infection, Brasília, 120pp.
26. Duran AC, Almeida LB, Segurado AA et al. Diet quality of persons living with HIV/AIDS on highly active antiretroviral therapy. J Hum Nutr Diet 2008, 21:346-50
27. Calza L, Manfredi R, Chiodo F. Dyslipidemia associated with antiretroviral therapy in HIV-infected patients. J Antimicrob Chemother 2004, 53:10-4.